European Commission logo
English English
CORDIS - EU research results
CORDIS

Article Category

News
Content archived on 2023-03-06

Article available in the following languages:

EN

A Key for Succes: Removing Intellectual Property Bottlenecks for Commercialization of Life Science Research

A set of indicators for the assessment of commercially viable public-private collaborative projects in Life sciences has been developed within the Bridge-BSR FP7 project by the the Steinbeis-Transfer-Institute for IP Management in collaboration with Steinbeis Team North East.

This will significantly improve the possibilities for successful trans-national knowledge transfer in ScanBalt BioRegion. The Steinbeis-Transfer-Institute for IP Management in collaboration with Steinbeis Team North East has developed a set of indicators for the assessment of commercially viable public-private collaborative projects in Life sciences. This will significantly improve the possibilities for successful trans-national knowledge transfer in ScanBalt BioRegion. The indicators targets four main dimensions namely technology, intellectual property, the market situation and the exploitation of technology transfer options. The development of the indicators is part of the EU FP 7 Co-funded project Bridge-BSR. Frank Graage, Head of Steinbeis Team North East says “With the development of indicators we have taken a major step forward towards bridging Life science academic research and SMEs in ScanBalt BioRegion. We will now implement the indicators within e.g. environmental life sciences as this has priority in order to support the development of a strong eco-industrial sector. Overall, this promotes an effective Eco-agenda for the Baltic Sea Region and assist to establish the region as a global frontrunner within a sector, which is likely to boom the coming years”. The summary of the report on indicators can be downloaded at http://www.scanbalt.org/graphics/ScanBalt/Activities/BridgeBSR/09-02-09_Executive_Summary_BridgeBSR_WP2_Indicators.pdf For further information on the full report please contact Stephan Hundertmark at Tel +49 (0) 89 / 74 63 92 - 19 or e-mail stephan.hundertmark@stiipm.de For further information on Bridge-BSR please see http://www.scanbalt.org/sw14944.asp For further information on ScanBalt BioRegion, please see www.scanbalt.org. At the end of 2008 ScanBalt BioRegion had 2393 life science companies.

Countries

Austria, Belgium, Bulgaria, Cyprus, Czechia, Germany, Denmark, Estonia, Greece, Spain, Finland, France, Hungary, Ireland, Italy, Lithuania, Luxembourg, Latvia, Malta, Netherlands, Poland, Portugal, Romania, Sweden, Slovenia, Slovakia, United Kingdom